[
  {
    "ts": null,
    "headline": "Top Research Reports for Lowe's, Bristol-Myers & Marvell Technology",
    "summary": "Lowe's leans on Pro-focused strategy and AI-powered retail tools, Bristol-Myers banks on new drug launches to offset legacy declines, and Marvell rides AI-driven data center growth despite consumer softness.",
    "url": "https://finnhub.io/api/news?id=a2d373e2b4c160acf7ac58ce04e5f03e0e531e296f03be011370a8faf0ee90bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755291300,
      "headline": "Top Research Reports for Lowe's, Bristol-Myers & Marvell Technology",
      "id": 136376439,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Lowe's leans on Pro-focused strategy and AI-powered retail tools, Bristol-Myers banks on new drug launches to offset legacy declines, and Marvell rides AI-driven data center growth despite consumer softness.",
      "url": "https://finnhub.io/api/news?id=a2d373e2b4c160acf7ac58ce04e5f03e0e531e296f03be011370a8faf0ee90bb"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca Rides Oncology Momentum With Blockbuster and New Drugs",
    "summary": "AstraZeneca's oncology sales jump 18% in second-quarter 2025, fueled by key drugs and new launches like Truqap and Datroway.",
    "url": "https://finnhub.io/api/news?id=8c7ecaa4347c659d636f57fb74c8536477449124626665b52fa7ca9f7ad73eeb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755266400,
      "headline": "AstraZeneca Rides Oncology Momentum With Blockbuster and New Drugs",
      "id": 136370262,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "AstraZeneca's oncology sales jump 18% in second-quarter 2025, fueled by key drugs and new launches like Truqap and Datroway.",
      "url": "https://finnhub.io/api/news?id=8c7ecaa4347c659d636f57fb74c8536477449124626665b52fa7ca9f7ad73eeb"
    }
  },
  {
    "ts": null,
    "headline": "Dogs Of The S&P 500: Buy 19 Ideal \"Safer\" August Dividend Payers",
    "summary": "Many high-yield S&P 500 stocks are risky, but 19 'safer' dividend dogs have strong free cash flow to support payouts and are worth considering. Read our list of August stock picks here.",
    "url": "https://finnhub.io/api/news?id=6a4ab244bbce8541a9adcdaa673191de493c7b6f89fcf98986531e01f0c4f684",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755264868,
      "headline": "Dogs Of The S&P 500: Buy 19 Ideal \"Safer\" August Dividend Payers",
      "id": 136370811,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2223715508/image_2223715508.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Many high-yield S&P 500 stocks are risky, but 19 'safer' dividend dogs have strong free cash flow to support payouts and are worth considering. Read our list of August stock picks here.",
      "url": "https://finnhub.io/api/news?id=6a4ab244bbce8541a9adcdaa673191de493c7b6f89fcf98986531e01f0c4f684"
    }
  }
]